Thyrocare Technologies has approved the sale of its entire 100% stake in material wholly- owned subsidiary Nueclear Healthcare Limited (NHL) to Trovera Healthcare Private Limited for approximately ₹141.40 crore, subject to shareholder and other applicable approvals.
NHL operates the radiology and diagnostic imaging business of Thyrocare. The company said the divestment will allow it to focus its capital and management resources on its core pathology business.
The consideration comprises 42,500 compulsorily convertible preference shares (CCPS) of Trovera valued at ₹59.50 crore and cash consideration of approximately ₹81.90 crore, subject to working-capital adjustments. The CCPS will be issued at ₹14,000 per share and will represent around 4.5% of Trovera’s fully diluted share capital.
Trovera was incorporated in June 2026 and operates, or proposes to operate, in the healthcare and diagnostic services sector. The transaction is expected to be completed by November 30, 2026, subject to conditions precedent and requisite approvals.
For FY2025-26, NHL reported revenue of ₹44.62 crore, accounting for 5.38% of Thyrocare’s consolidated turnover. Its net worth stood at ₹83.55 crore as of March 31, 2026, representing 14.27% of Thyrocare’s consolidated net worth excluding non-controlling interest.
Separately, Thyrocare’s board approved the purchase of land and buildings in Gurugram, Haryana, and Hyderabad, Telangana, from NHL for ₹20.59 crore, excluding stamp duty, registration and other applicable charges. The properties currently house Thyrocare’s diagnostic laboratory facilities, and the acquisition is intended to secure continued ownership of these operating premises after the sale of NHL.
The property acquisition is proposed to be completed before or simultaneously with the divestment of NHL and is subject to shareholder approval.